The quality of reported earnings is more encouraging when judged against cash generation. Amgen generated $11.49 billion of operating cash flow and $10.39 billion of free cash flow in FY2024, implying a free cash flow margin of 31.11% (free cash flow divided by revenue). Put differently, Amgen’s operations produced meaningful cash available to fund R&D, dividends and debt service despite a year in which GAAP net income declined materially versus 2023. The FY2024 free cash flow figure underpins the company’s capacity to sustain shareholder distributions and fund late‑stage programs even while net income proved more volatile year‑over‑year.

There are, however, notable divergences between headline accounting metrics and balance‑sheet realities. Net income fell -39.11% YoY from $6.72 billion in 2023 to $4.09 billion in 2024, a decline driven by a combination of higher R&D ($5.96 billion, +~24.7% YoY) and elevated amortization and other charges tied to prior acquisitions. On a cash basis, operating cash flow rose +35.64% YoY and free cash flow grew +41.24% YoY, which demonstrates that non‑cash items and one‑time acquisition impacts were significant contributors to the earnings swing. These figures are contained in Amgen’s FY2024 reporting and the company’s cash‑flow statement Amgen FY2024 financials.

Table — Selected income statement metrics (FY2021–FY2024)#

Year	Revenue (USD)	Gross Profit (USD)	Operating Income (USD)	Net Income (USD)	Free Cash Flow (USD)
2024	33.42B	20.57B	7.26B	4.09B	10.39B
2023	28.19B	19.77B	7.90B	6.72B	7.36B
2022	26.32B	19.92B	9.57B	6.55B	8.79B
2021	25.98B	19.52B	7.64B	5.89B	8.38B

(Values taken from Amgen FY filings and public investor materials filed Feb 14, 2025) Amgen FY2024 financials.

Balance sheet and leverage: calculations and a transparency note#

At fiscal year‑end 2024, Amgen reported total assets of $91.84 billion, total liabilities of $85.96 billion, and total stockholders’ equity of $5.88 billion, producing a balance‑sheet structure that is asset‑heavy and equity‑light relative to historical norms. The company carried total debt of $60.10 billion and cash & equivalents of $11.97 billion, which yields net debt of $48.13 billion (total debt minus cash). Using FY2024 EBITDA of $13.36 billion, the net debt/EBITDA multiple calculated from these fiscal figures is 3.60x (48.13 / 13.36). That ratio is materially higher than some reported TTM metrics in third‑party feeds; differences arise because providers use differing trailing windows, pro forma adjustments, or alternative EBITDA definitions. We flag that difference explicitly: our calculation uses the company’s FY2024 EBITDA and year‑end net debt reported in the FY2024 filing.

Similarly, a straightforward debt‑to‑equity calculation using total debt divided by reported equity gives total debt / equity ≈ 10.22x (60.10 / 5.88), or 1,022% on a percentage basis — a level that communicates the leverage intensity when goodwill and intangible assets dominate book equity. These leverage computations highlight why future cash‑flow conversion and debt servicing are central to the investment case: the balance sheet leaves less room for missteps.

Table — Balance sheet & leverage (FY2024, calculated ratios)#

Metric	Reported Value	Our Calculation
Cash & Equivalents	11.97B	—
Total Debt	60.10B	—
Net Debt	48.13B	total debt - cash = 48.13B
EBITDA (FY2024)	13.36B	—
Net Debt / EBITDA	—	3.60x (48.13 / 13.36)
Debt / Equity	—	10.22x (60.10 / 5.88)
Current Ratio	1.26x	total current assets / total current liabilities = 29.03 / 23.10 = 1.26x

(Primary figures from Amgen FY2024 balance sheet; ratios computed above.) Amgen FY2024 financials.

Why the Q2 beat matters: product momentum and the path to durable cash flow#

Amgen’s Q2 strength is not reliant on a single product. Management pointed to volume‑driven gains across a wide set of franchises, with notable commercial momentum from Repatha (lipid lowering), early uptake for Imdelltra in oncology, and continued traction in biosimilars. Repatha’s broader FDA label (expanded indication secured in 2023) translated into meaningful volume gains: by 2025 Repatha sales were reported near $696 million with 36% volume growth in the period described in market commentary, confirming that label expansion can accelerate utilization when payers and prescribers align with clinical guidance AInvest Repatha analysis.

Imdelltra’s early commercial performance — roughly $215 million in H1 2025 sales as reported in industry commentary — and the subsequent royalty monetization (up to $950 million of royalty interest acquired by Royalty Pharma, with an $885 million upfront payment reported) operate as dual evidence: the asset has commercial traction and third‑party investors are willing to place capital behind longer‑term royalty streams. The Royalty Pharma transaction validates Imdelltra’s market potential even though the monetization proceeds did not flow directly to Amgen’s balance sheet; product sales continue to accrue to Amgen while the royalty buyer assumes a portion of the long‑term cash flow in exchange for upfront liquidity to the royalty holder Quiver Quant/Royalty Pharma coverage.

Most consequential longer‑term is MariTide, Amgen’s monthly obesity candidate. Phase 2 demonstrated average weight loss near 20% at 52 weeks, which is a differentiated efficacy signal in an increasingly crowded obesity market. Amgen launched two Phase 3 trials in early 2025 (MARITIDE‑1 and MARITIDE‑2) with primary readouts planned for early 2027, and optimistic peak‑sales scenarios voiced by some analysts cluster around $5 billion annually for a best‑case MariTide outcome Amgen press release, MariTide Phase 2 results and broader industry coverage (FierceBiotech, ClinicalTrialsArena).

Competitive dynamics: PCSK9, obesity and biosimilars#

The cardiometabolic and obesity spaces are now battlegrounds. In PCSK9 inhibition, Repatha competes with Praluent and the siRNA entrant Leqvio (inclisiran). Leqvio’s twice‑yearly dosing profile and potential cost advantages present a structural headwind to monthly or more frequent injectable PCSK9 incumbents, forcing Amgen to defend with label expansion, pricing structures and combination strategies. In obesity, MariTide faces a deep competitive moat from Novo Nordisk and Eli Lilly, both of which have market‑moving products and significant payer relationships. Amgen’s differentiator — monthly dosing with high efficacy signals — could translate to a durable commercial position if tolerability, real‑world adherence and health‑economics check out in Phase 3 and payer negotiations.

Biosimilars remain a second structural risk across mature franchises such as Prolia. Biosimilar entrants can produce rapid share and price erosion; Amgen attempts to blunt this via portfolio diversification and by leaning into higher‑value, newer launches, but the threat is persistent.

Capital allocation: dividends, buybacks and debt paydown#

Amgen continues to return cash to shareholders through a robust dividend program: the company’s trailing dividend per share is $9.39 annually (dividend yield roughly +3.26%) with quarterly payments of $2.38 in 2025 so far. That payout represents a high proportion of GAAP earnings on a per‑share basis (9.39 / reported EPS ≈ +76.86% using EPS ≈ 12.22), and cash dividends paid in FY2024 totaled $4.83 billion, which actually exceeded FY2024 net income of $4.09 billion — a fact that highlights how Amgen’s dividend is funded from free cash flow rather than GAAP earnings alone Amgen FY2024 cash flow statement.

The company repurchased only $200 million of stock in FY2024 versus multi‑billion buybacks in prior years; that change reflects management’s implicit prioritization of balance‑sheet repair and funding for acquisitions/pipeline investment after large M&A and royalty/asset purchases in prior years. With net debt at $48.13 billion, the challenge for capital allocation is clear: Amgen must balance R&D and pipeline investments (MariTide, olpasiran, oncology assets) with the need to reduce leverage or at least stabilize it while maintaining the dividend.

Valuation multiples: calculated and contrasted#

Using public market data and FY2024 results, Amgen’s market capitalization was approximately $155.32 billion (stock quote snapshot), and enterprise value (EV) using our calculation (market cap + total debt - cash) is roughly $203.45 billion (155.32 + 60.10 - 11.97). Dividing that EV by FY2024 EBITDA ($13.36 billion) yields an EV/EBITDA of ~15.24x. This is higher than some third‑party TTM multiples reported in data feeds (for example, a reported EV/EBITDA of 12.77x), and the variance stems from differences in EBITDA definitions, trailing windows, and whether pro forma adjustments for acquisitions are included. Our point estimate relies on the company’s FY2024 EBITDA and year‑end balance‑sheet items; investors should be explicit about denominator and window when comparing multiples across providers.

Free cash flow yield computed from FY2024 free cash flow (10.39B) divided by market cap (155.32B) is ~6.69%, a meaningful cash yield that supports distributions and deleveraging if management prioritizes that path.

Risks, disclosure and near‑term catalysts#

Material downside risks are clear and data‑driven. A larger‑than‑expected erosion from biosimilars on mature franchises, tougher payer restrictions for high‑cost cardiometabolic and obesity therapies, or clinical setbacks in MariTide/other late‑stage programs would compress revenue and make debt servicing more onerous. Conversely, continued double‑digit volume growth across multiple launches, durable payer coverage for Repatha and Imdelltra, or a strong Phase 3 outcome for MariTide would materially improve cash‑flow visibility and deleveraging prospects.

Near‑term catalysts to watch (with measurable data points) include sequential Repatha volume and revenue trends in upcoming quarters, Imdelltra H2 2025 commercial cadence, and enrollment and interim messaging from the MARITIDE Phase 3 program leading into early 2027 readouts. The company’s next formal earnings announcement and any investor‑day updates will also clarify management’s capital‑allocation priorities for the coming 12–24 months Amgen Q2 materials.

What this means for investors (data‑anchored implications)#

Amgen’s Q2 2025 beat and raised guidance validate current commercial execution: volume growth and portfolio depth are real, and near‑term revenue momentum is measurable. However, the FY2024 balance sheet shows high net leverage (net debt ≈ $48.13B) and significant intangible assets that compress book equity, which means the company must demonstrate cash‑flow conversion from new launches to justify both the dividend profile and current multiples. Investors should treat free cash flow (absolute dollars and margin) and leverage reduction (or stabilization) as the primary evidence of strategic success, not GAAP earnings alone.

Operationally, Repatha and Imdelltra provide tangible commercial upside in the near term, while MariTide is a meaningful longer‑term optionality with outsized revenue potential if Phase 3 confirms Phase 2 efficacy and payers accept chronic pharmacotherapy economics. Because Amgen’s dividend is substantial on a per‑share basis, the company’s ability to sustain distributions depends more on free cash flow and balance‑sheet management than on headline net income in any single year.

Conclusion — measured confidence contingent on cash conversion#

Amgen’s Q2 performance was a clear example of effective commercial execution: broad volume gains, a substantive beat on revenue and EPS, and a lifted revenue outlook for FY2025. Those operational wins are real and underpinned by discrete assets — Repatha’s label expansion, Imdelltra’s early uptake and third‑party royalty interest, and MariTide’s high‑impact Phase 2 data — that together create a plausible path to stronger top‑line growth.

At the same time, the balance‑sheet and valuation computations demand discipline. Our independent calculations show a net debt/EBITDA ~3.60x, an EV/EBITDA ~15.24x, and a free cash flow yield near +6.69%, metrics that frame the company’s capacity to invest, pay dividends, and reduce leverage. The investment story is therefore conditional: recent execution buys management runway, but the company must convert pipeline promise into predictable cash flow and demonstrate progress on leverage to fully justify current multiples. The next set of commercial readouts and the progression of MariTide’s Phase 3 program are the clearest, data‑driven inflection points to watch.

(For source documentation and full filings cited throughout this report, see Amgen’s investor materials and Q2 earnings call transcript linked earlier: Amgen investor presentation, earnings call transcript. Additional coverage of Repatha, Imdelltra and MariTide cited in the analysis is drawn from industry reporting and press releases referenced in the body.)